Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: A systematic review and meta-analysis

Waleed Khokher1 | Azizullah Beran1 | Saffa Iftikhar1 | Saif-Eddin Malhas1 | Omar Srour1 | Mohammed Mhanna1 | Sapan Bhuta1 | Dipen Patel1 | Nithin Kesireddy1 | Cameron Burmeister1 | Elizabeth Borchers2 | Ragheb Assaly1,3 | Fadi Safi3

1Department of Internal Medicine, University of Toledo, Toledo, Ohio, USA
2Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA
3Department of Pulmonary and Critical Care Medicine, University of Toledo, Toledo, Ohio, USA

Correspondence
Waleed Khokher, Department of Internal Medicine, University of Toledo, Toledo, OH, USA.
Email: waleed.khokher@utoledo.edu

Abstract
Systemic steroids are associated with reduced mortality in hypoxic patients with coronavirus disease 2019 (COVID-19). However, there is no consensus on the doses of steroid therapy in these patients. Several studies showed that pulse dose steroids (PDS) could reduce the progression of COVID-19 pneumonia. However, data regarding the role of PDS in COVID-19 is still unclear. Therefore, we performed this meta-analysis to evaluate the role of PDS in COVID-19 patients compared to nonpulse steroids (NPDS). Comprehensive literature search of PubMed, Embase, Cochrane Library, and Web of Science databases from inception through February 10, 2022 was performed for all published studies comparing PDS to NPDS therapy to manage hypoxic patients with COVID-19. Primary outcome was mortality. Secondary outcomes were the need for endotracheal intubation, hospital length of stay (LOS), and adverse events in the form of superimposed infections. A total of 10 observational studies involving 3065 patients (1289 patients received PDS and 1776 received NPDS) were included. The mortality rate was similar between PDS and NPDS groups (risk ratio [RR]: 1.23, 95% confidence interval [CI]: 0.92–1.65, p = 0.16). There were no differences in the need for endotracheal intubation (RR: 0.71, 95% CI: 0.37–1.137, p = 0.31), LOS (mean difference: 1.93 days; 95% CI: −1.46–5.33; p = 0.26), or adverse events (RR: 0.93, 95% CI: 0.56–1.57, p = 0.80) between the two groups. Compared to NPDS, PDS was associated with similar mortality rates, need for endotracheal intubation, LOS, and adverse events. Given the observational nature of the included studies, randomized controlled trials are warranted to validate our findings.

KEYWORDS
corticosteroids, COVID-19, hospital stay, intubation, mortality, pulse dose steroids

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, first discovered in China in December 2019, and has become a worldwide pandemic leading to significant morbidity and mortality.\(^1\)\(^2\) The acute respiratory distress syndrome (ARDS) due to viral pneumonitis is one of the leading causes of mortality among patients with COVID-19.\(^3\) ARDS occurs in 33% of hospitalized patients with COVID-19 and 75% of those who required ICU admission.\(^4\) The average mortality rate among COVID-19 patients with ARDS is 39% (ranging from 13% to 73%).\(^5\)

In the absence of specific antiviral therapy for COVID-19, research on the effectiveness of various re-purposed drugs in COVID-19 has become an urgent task of scientists and physicians. Exaggerated inflammatory response with cytokine storm is the hallmark of moderate to severe cases of COVID-19.\(^6\) In July 2020, the RECOVERY trial showed that low-dose dexamethasone reduced mortality in patients with COVID-19 who need oxygen supplementation.\(^7\) Since then, many studies have been conducted and demonstrated that systemic steroids were associated with reduced mortality in hypoxic patients with COVID-19.\(^8\)\(^9\) Systemic steroids work by decreasing the expression of pro-inflammatory cytokines, thus reducing the IL-6 mediated cytokine storm, which prevents further progression of ARDS.\(^10\) However, the role of pulse dose steroids (PDS) in ARDS patients is not well established. PDS entails the use of glucocorticoids, usually methylprednisolone (MTP), delivered at very high doses of 10–20 mg/kg or >250 mg/day and as high as 1 g/day.\(^11\) The use of PDS has been well studied during the SARS and MERS epidemics, with the results being controversial.\(^12\)\(^13\) The theory behind using PDS steroids is that the high dose of steroids can counter the hyperinflammatory phase COVID-19 and can help to reduce mortality.\(^14\)\(^15\)

Although systemic steroids have shown a mortality benefit in COVID-19, there is no consensus on the doses of steroids therapy in these patients. Newer studies showed that PDS could reduce the progression of COVID-19.\(^16\)\(^17\)\(^18\)\(^19\) Several studies have compared PDS versus nonpulse dose steroids (NPDS) with conflicting results.\(^20\)\(^21\)\(^22\)\(^23\) Data regarding the role of PDS in COVID-19 are still unclear. Therefore, we performed this meta-analysis to evaluate the effect of PDS versus NPDS on the clinical outcomes of patients with COVID-19 pneumonia.

2 | METHODS

2.1 | Data sources and search strategy

We performed a comprehensive search for published studies indexed in PubMed/MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science from inception to February 10, 2022. We also performed a manual search for additional relevant studies using references of the included articles. The following search terms were used: ("pulse dose" or "high dose"), ("methylprednisolone" or "dexamethasone" or "hydrocortisone" or "prednisone" or "glucocorticoids" or "steroids"), and ("COVID" or "COVID-19"). The search was not limited by language, study design, or country of origin. Supporting Information: Table S1 describes the full search terms used in each database searched.

2.2 | Inclusion and exclusion criteria

All peer-reviewed studies that compared PDS versus NPDS in COVID-19 patients and reported one of the following outcomes: mortality, need for endotracheal intubation, length of stay (LOS), or adverse events were eligible for inclusion. PDS therapy should be clearly defined and must meet the following criteria: a dose of >250 mg of methylprednisolone (MTP) or 5–10 mg/kg/day of MTP or an equivalent dose of glucocorticoids (GC) must be administered to >75% of the PDS group for at least two consecutive days. NPDS cohort should receive any dose less than the PDS doses. We excluded single-arm studies, case reports, case series, reviews, editorials, abstracts, and preprint studies.

2.3 | Data extraction

The following data were extracted from the studies: first author name, publication year, country of origin, study design, sample size, gender of patients, mean age, and underlying comorbidities of the patients, including asthma and other chronic lung diseases, malignancy, coronary artery disease, and chronic kidney disease or acute kidney injury. We also obtained inclusion criteria in each study and respiratory support used in each study. For each arm of the study, the detailed PDS and NPDS treatment regimens were extracted. Outcomes measures were also retrieved, including mortality, need for endotracheal intubation, LOS, and superimposed infection.

2.4 | Outcomes

The primary outcome of our study was mortality. The secondary outcomes were the need for endotracheal intubation, LOS, and adverse events in the form of superimposed infections or bacterial growth in cultured bodily fluids.

2.5 | Statistical analysis

We performed a meta-analysis of the included studies using Review Manager 5.3 (Cochrane Collaboration, Copenhagen, The Nordic Cochrane Centre) and Comprehensive Meta-Analysis (Biostat). The random-effects model was used to calculate the pooled risk ratio (RR) and mean difference (MD) with the corresponding confidence intervals (CIs) for proportional and continuous variables, respectively.
A p < 0.05 was considered statistically significant. The heterogeneity of the effect size estimates across the studies was quantified using the Q statistic and $I^2$ ($p < 0.10$ was considered significant). A value of $I^2$ of 0%–25% indicates significant homogeneity, 26%–50% low homogeneity, and >50% indicates heterogeneity.20

### 2.6 Sensitivity and subgroup analyses

To confirm the robustness of the results, sensitivity analysis for all outcomes (mortality, need for endotracheal intubation, LOS, and adverse events) using a leave-one-out meta-analysis was performed to see if it had a significant influence on the result of the meta-analysis. Subgroup analysis was performed for studies that only included patients who received dexamethasone (DEXA) only in the NPDS group and based on the PDS therapy strategy (initial vs. rescue therapy) for mortality.

### 2.7 Bias assessment

We assessed the quality of the included studies using the Newcastle-Ottawa Scale (NOS) for observational studies.21 Two authors (W. K. and A. B.) independently assessed each study for bias. Discrepancies were resolved by a third reviewer (O. S.). Publication bias was assessed for mortality qualitatively by visualizing the funnel plot and quantitatively using Egger’s regression analysis. A p-value was generated using the Egger analysis, and a value of <0.05 was associated with significant publication bias.

### 3 RESULTS

#### 3.1 Study selection

A total of 10,130 studies were retrieved by our search strategy. Seven thousand two hundred fifty-three studies were excluded based on the title and abstract review. A total of 1568 studies underwent full-length review. Subsequently, we excluded 1558 studies because of the following: 1391 studies used inappropriate doses of steroids or lacked the appropriate comparison, 128 studies did not report data regarding the interventions of interest, and 39 studies were excluded due to lack of the appropriate outcomes of interest. Eventually, 10 studies met our inclusion criteria and were included in the meta-analysis.14–19,22–25 Figure 1 shows the preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart that illustrates how the final studies were selected.

#### 3.2 Study and patient characteristics

Table 1 shows the baseline characteristics of the studies included in the meta-analysis. All the studies were published between August 2020 and December 2021 and included COVID-19 patients confirmed by laboratory testing or imaging. Based on country of origin: five studies originated from Europe (Italy: 1; Spain: 2; and Turkey: 2), one from Morocco, one from Colombia, one from Japan, one from Pakistan, and one from the United States. Nine studies were retrospective cohort, while one was an ambispective cohort.

A total of 3065 patients (1289 patients received PDS and 1776 received NPDS) were included, with males representing 61.8% of the total patients. The mean age of the patients in the PDS group was 56.1 years, and 65 years in the NPDS group. The follow-up period across the studies ranged from 14 to 46 days.

#### 3.3 Mortality

Table 2 summarizes the outcomes of the individual studies included in the meta-analysis. All 10 studies14–19,22–25 reported the mortality rate. The mortality rate was 30.1% in the PDS group compared to 23.7% in the NPDS group. There was no significant difference in the mortality rate between the two groups (RR: 1.23, 95% CI: 0.92–1.65, $p = 0.16$, $I^2 = 81\%$, Figure 2A). A subgroup analysis of studies that included only DEXA in the NPDS group showed similar mortality rates between the two groups (RR: 0.91, 95% CI: 0.91–2.30, $p = 0.84$, $I^2 = 79\%$, Figure 3A). Subgroup analysis also showed no significant difference if PDS was given as initial therapy or rescue therapy (Figure 3B). A leave-one-out sensitivity analysis showed consistent results (Supporting Information: Figure S1A).

#### 3.4 Need for endotracheal intubation

Across the four studies14,15,17,19 that reported the intubation rate; 23.3% of patients who received PDS required intubation compared to 26.2% in patients who received NPDS. The need for endotracheal intubation was similar between PDS and NPDS groups (RR: 0.71, 95% CI: 0.37–1.137, $p = 0.31$, $I^2 = 88\%$, Figure 2B). Consistent results were shown on sensitivity analysis (Supporting Information: Figure S1B).

#### 3.5 Length of hospital stay

Three studies17,19,23 reported the LOS. There was no significant difference in the LOS between the two groups (MD: 1.93 days; 95% CI: −1.46–5.33; $p = 0.26$, $I^2 = 91\%$, Figure 2C). The results were consistent on the leave-one-out sensitivity analysis (Supporting Information: Figure S1C).

#### 3.6 Adverse events

Four studies14,19,23,24 reported the adverse events in the form of superimposed infection or bacterial growth in bodily fluid cultures. These events were similar between the PDS and NPDS groups (RR:
3.7 | Quality and publication bias assessment

We followed the PRISMA statement flow diagram model to select the final studies. Two investigators (W. K. and A. B.) independently performed the search and shortlisted the studies for final review. Discrepancies were resolved by a third reviewer (O. S.). Quality assessment scoring of the included studies was performed using the NOS for assessing nonrandomized studies, and the scores are summarized in Supporting Information: Table S2. All the included studies were of high quality. There was a visible asymmetry in the funnel plot of the studies that reported mortality, which may suggest the presence of publication bias (Supporting Information: Figure S2). However, Egger’s regression analysis did not demonstrate statistically significant publication bias (p = 0.86).

4 | DISCUSSION

This is the first meta-analysis comparing PDS and NPDS regimens in patients with COVID-19 and showed no significant differences between PDS and NPDS regimens in terms of mortality, need for endotracheal intubation, LOS, and adverse events.

Since the RECOVERY trial showed a mortality benefit with steroid therapy due to its anti-inflammatory and immunomodulatory effects, steroid therapy (equivalent dose of 6 mg dexamethasone [DEXA]) became a standard treatment in most hospitals for COVID-19 patients requiring oxygen support. A recent meta-analysis by Li et al.7 revealed consistent results with a significant reduction in mortality among patients with severe COVID-19, especially when administered earlier.

Although steroid therapy is a common practice in the current management of COVID-19, there are current debates on the dose of the corticosteroids that should be used in these patients. In an RCT by Edalatifard et al.,26 including 68 patients with COVID-19, the PDS group (received methylprednisolone therapy at a dose of 250 mg/day for 3 days) had a lower mortality rate and shorter recovery duration as compared to the control group. The rationale of using PDS therapy is to get a quicker and stronger anti-inflammatory response, thus reducing the need for a prolonged course of steroids.7
| Study (year)                  | Batirel (2021) | Fernandez-Cruz (2020) | El mezzeoui (2021) | Gundogdu (2021) | Jamil (2021) | Monreal (2021) | Pinzon (2021) | Toda (2021) | Umbrello (2021) | Yaqoob (2021) |
|------------------------------|----------------|-----------------------|--------------------|-----------------|--------------|----------------|---------------|-------------|----------------|----------------|
| Study design                 | Retrospective cohort | Retrospective cohort | Retrospective cohort | Retrospective cohort | Retrospective cohort | Retrospective cohort | Ambispective cohort | Retrospective cohort | Retrospective cohort | Retrospective cohort |
| Country                      | Turkey          | Spain                 | Morocco            | Turkey          | Pakistan     | Spain          | Colombia      | Japan      | Italy          | USA            |
| Total patient (PDS/NPDS)     | 300 (150/150)   | 396 (86/310)          | 513 (283/230)      | 400 (200/200)   | 433 (209/224) | 573 (177/396)  | 216 (105/111) | 17 (8/9)   | 80 (22/58)    | 136 (49/87)   |
| PDS group age, mean ± SD, years | 59.4 ± 17.0    | 65.4 ± 12.9 for all steroid recipients | 62.9 ± 15.7        | 66.9 ± 12.2     | 55.9 ± 17.0  | 65.9 ± 15.7    | 64.0 ± 6.0    | 59.5 ± 17.8 | 61 ± 8        | 66 ± 13       |
| NPDS group age, mean ± SD, years | 59.9 ± 16.6    | 64.4 ± 14.9           | 71.3 ± 11.1        | 63.3 ± 13.4     | 63.4 ± 8.3   | 77.0 ± 14.0    | 60 ± 10       | 60 ± 16     |               |               |
| Male in PDS group, n (%)     | 100 (67)       | 276 (69.7)            | 190 (67.3)         | 135 (67.5)      | 100 (23.1)   | 150 (84.8)     | 67 (63.8)     | 8 (100)     | 19 (86.4)     | 27 (55)       |
| Male in NPDS group, n (%)    | 100 (67)       | 162 (70.4)            | 111 (55.5)         | 278 (70.2)      | 60 (54.1)    | 6 (67)         | 48 (84.8)     | 60 (69)     |               |               |
| Patient inclusion criteria   | Nonmechanically ventilated patients with no current bacterial or fungal infections, and not having received any other anti-cytokine, anti-inflammatory or a steroid regimen other than the intended group defined steroid treatments | All patients initially admitted to the ICU and stayed in the hospital for >7 days | Patients who did not receive another anti-inflammatory, anti-cytokine, or receive any inappropriate doses of glucocorticoids that were intended as part of the study | Patients with evidence of ARDS and/or had laboratory evidence of hyper-inflammatory syndrome | Patients with evidence of ARDS or >50% of total lung fields showing infiltrates on chest x-ray. Patients also had to not have received previous recent course of steroids, tocilizumab, or have any contraindications to steroids treatment | Patients who did not receive remdesivir and had confirmed ARDS via the Berlin criteria | Patients who required supplemental oxygen, were able to receive adequate steroid treatment as defined by the treatment protocol of the study | Patients admitted to the ICU with a primary diagnosis of COVID-19 pneumonia to the ICU, were started on steroids within 48 h of ICU admission and received > 1 pulse dose of steroid | Patients admitted to the ICU with a primary diagnosis of COVID-19 pneumonia to the ICU, were started on steroids within 48 h of ICU admission and received > 1 pulse dose of steroid | (Continues) |
| Hospital location | Non-ICU patients | ICU patients | ICU patients | NR | Non-ICU patients | NR | ICU patients | ICU patients |
|-------------------|------------------|--------------|--------------|----|------------------|----|--------------|--------------|
| Ventilation status before steroid regimen | No patient on IMV | Most patients not on IMV | NPDS group: No patient on IMV | NR | 12/433 patients on IMV; 32/433 patients on NIV | NPDS group: 11 patients on NIV or IMV | NR | All patients were on IMV | NPDS group: 70 patients on IMV |
| Days from symptom onset to intervention (PDS/NPDS) | 6.5 ± 4.9/7.0 ± 4.5 | 10.4 ± 3.7 for all steroid recipients | NR | NR | NR | NR | 7.5 ± 6.8/7.0 ± 3.0 | NR |
| Other relevant treatments specified | Antibiotics (not specified), azithromycin, doxycycline, tocilizumab, anakinra | Azithromycin, doxycycline, tocilizumab, favipiravir | NR | NR | NR | NR | Azithromycin, HCQ |
| PDS regimen | Patients who did not respond positively to NPDS therapy after 3 days of treatment with either clinical or radiologic improvement were given rescue PDS therapy with 250 mg/day of MTP for 3 days, followed again by NPDS therapy to complete a 10-day course | Patients received 3 days of PDS therapy with either 250 mg/day (62.5%) of MTP or 500 mg/day (17.1%) of MTP | 6 mg/kg/day of DXM for 7 days | 1 g/day of MTP for 3 days followed by 80 mg/day of MTP | 500 mg/day of MTP for 10 days | 250 mg to 1 g per day of MTP or an equivalent steroid dose for 1 or more consecutive days | Days of mean ± SD for treatment was 5.8 ± 9.0 | IV 250 mg to 500 mg per day of MTP for 3 days followed by oral prednisone 50 mg/day for the next 14 days | Patients who did not respond positively to NPDS therapy and went on to require O2 > 8 L/min and needed HFNO, or MV were given rescue PDS therapy with either 1 g/day of IV MTP for 3 days, within the first 10 days of initiating high dose steroid | Patients received 1 g/day of MTP. Timing and number of doses varied based on clinical condition |
TABLE 1 (Continued)

| NPDS regimen | DXM 6 mg/day or equivalent dose of any steroid for 10 days | 1 mg/kg/day of MTP or an equivalent steroid | 1 mg/kg/day of MTP for 7 days | DXM 8 mg/day or MTP 80 mg/day | DXM 6 mg or more per day for 10 days | 0.5–1.5 mg/kg/day of MTP or an equivalent steroid dose | IV DXM 6 mg/day for 10 days | DXM 6 mg/day until clinical improvement | DXM 20 mg/day for the first 7 days, followed by 10 mg/day for the next 7 days to complete a 14-day treatment course. Or MTP 1 mg/kg/day for 14 days | 0.5–2 mg/kg/day of MTP or an equivalent steroid dose |
|---------------|----------------------------------------------------------|---------------------------------------------|-----------------------------|--------------------------------|-----------------------------------|----------------------------------------|--------------------------------|----------------------------------------|------------------------------------------------|--------------------------------------------------|
| Follow-up duration | 28 days | 30 days | NR | NR | 30 days | Median 21 days | 30 days | Mean 27 days (range: 14–46) | NPDS group: Median 27 days | PDS group: Median 21 days |
| Underlying comorbidities | Asthma and other chronic lung diseases (PDS/NPDS) | 15/21 | 71 of the total 396 steroid recipients | NR | NR | 38 of the total 433 steroid recipients | 32/62 | 11/12 | 2/1 | NR | 1/11 |

Followed by tapering steroid treatment with DXM based on clinical condition.
| Condition                  | Abbreviations | Numbers | Total | Numbers | Total | Numbers | Total | Numbers | Total | Numbers | Total |
|----------------------------|----------------|---------|-------|---------|-------|---------|-------|---------|-------|---------|-------|
| Malignancy (PDS/NPDS)      |                | 14/16   | NR    | NR      | 18    | 22/35   | 6/7   | 2/1     | NR    | 9/6     |
| CAD (PDS/NPDS)             |                | 27/30   | 39/32 | NR      | 42    | 36/63   | 9/10  | NR      | NR    | 2/10    |
| CKD or AKI (PDS/NPDS)      |                | 10/8    | 17/15 | NR      | 56    | 17/28   | 7/13  | 3/2     | NR    | 2/12    |

Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; DXM, dexamethasone; HCQ, hydroxychloroquine; ICU, intensive care unit; IMV, invasive mechanical ventilation; IV, intravenous; MTP, methylprednisolone; NIV, noninvasive ventilation; NPDS, nonpulse dose steroids; NR, not reported; PDS, pulse dose steroids; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.
| Study (year)         | In-hospital mortality | Need for mechanical ventilation | Hospital length of stay (days) | Adverse events |
|---------------------|-----------------------|---------------------------------|--------------------------------|----------------|
|                     | PDS (%)               | NPDS (%)                        | PDS (%)                       | NPDS (%)       |
| Batirel (2021)      | 14/150 (9.3)          | 16/150 (10.7)                   | 16/150 (10.7)                 | 13/150 (8.7)   |
|                     |                       |                                 | 12 (4.5)                      | 7.7 (4.5)      |
| Cruz (2020)         | 13/86 (15.1)          | 42/310 (13.5)                   | -                             | -              |
| El mezzeoui (2021)  | 79/283 (27.9)         | 82/230 (35.7)                   | 41/283 (14.5)                 | 55/230 (23.9)  |
|                     |                       |                                 | -                             | -              |
| Gundogdu (2021)     | 117/200 (58.5)        | 107/200 (53.5)                  | 112/200 (56.0)                | 91/200 (45.5)  |
|                     |                       |                                 | 12.06 (6.85)                  | 11.54 (5.98)   |
| Jamil (2021)        | 43/209 (20.6)         | 13/176 for the DXM 6 mg/day group, 17/48 for those receiving >6 mg/day DXM. Overall, 30/224 (13.4) |
| Monreal (2021)      | 69/177 (39.0)         | 74/396 (18.7)                   | -                             | -              |
| Pinzon (2021)       | 10/105 (9.5)          | 19/111 (17.1)                   | 3/105 (2.9)                   | 22/111 (19.8)  |
| Toda (2021)         | 0/8 (0.0)             | 4/9 (44.4)                      | -                             | -              |
| Umbrello (2021)     | 17/22 (77.3)          | 20/59 (33.9)                    | -                             | 24.9 (16.6)    |
|                     |                       |                                 |                          | 26.1 (12.9)    |
| Yaqoob (2021)       | 26/49 (53.1)          | 27/87 (31.0)                    | -                             | 15/49 (30.6)   |

Abbreviations: NPDS, nonpulse dose steroids; PDS, pulse dose steroids.
Fernandez-Cruz et al.\textsuperscript{18} published the first comparative study between PDS and NPDS regimens in 2020, demonstrating no difference in mortality between PDS and NPDS regimens (15.1% and 13.5%, respectively). Since then, there have been a number of studies comparing the two regimens with controversial results. While several studies showed similar mortality rates between PDS and NPDS regimens,\textsuperscript{15–19} El mezzeoui et al. demonstrated significantly decreased mortality in the PDS group compared to NPDS. On the
contrary, Umbrello et al. found that PDS was associated with increased mortality compared to NPDS. Given the contradicting results of the studies in the literature, we conducted this meta-analysis to provide the first comprehensive evaluation and comparison of the two steroid therapy regimens for COVID-19 to address critical knowledge gaps in the management of COVID-19.

Our study results were consistent with a cohort study conducted by Ho et al. in 2003, which showed no differences in mortality or need for endotracheal intubation between PDS and NPDS in the management of patients with SARS. In this meta-analysis, we found similar results to those from a study by Gundogdu et al., which showed that PDS and NPDS were associated with similar mortality (58.5% and 53.5%, respectively). Furthermore, our meta-analysis results remained consistent on subgroup analysis based on the strategy of PDS therapy (initial vs. rescue therapy). Comparable to our results, Gundogdu et al. demonstrated similar rates of need for endotracheal intubation and LOS between the PDS and NPDS regimens.

There are several adverse events to using steroids, such as superimposed infections/bacterial overgrowth, hyperglycemia, and myopathy. In contrary to Umbrello et al., which showed an increased risk of infections with PDS regimen in addition to mortality, our meta-analysis showed similar rates of infection between the two regimens. The increased rates of infections within the PDS group in that study could be attributed to the fact that PDS was used as a rescue therapy after lack of response to NPDS regimen, indicating that the PDS group patients were sicker and had more severe features of COVID-19. In addition, PDS group had higher levels of C-reactive protein, IL-6, and D-dimer and a lower Partial pressure of arterial oxygen (PaO₂). Interestingly, we found that the infection rate was significantly lower in the PDS group upon removal of that study. This might be explained by the short duration of the PDS regimen.

### FIGURE 3

(A) Subgroup analysis of studies that included only dexamethasone in the NPDS group for mortality. (B) Subgroup analysis based on the strategy of pulse-dose steroid therapy (initial vs. rescue therapy) for mortality. NPDS, nonpulse dose steroids; PDS, pulse dose steroids.

| (A) | Study or Subgroup | PDS | NPDS (DEXA only) | Risk Ratio | Risk Ratio |
|-----|------------------|-----|-----------------|------------|------------|
|     | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
| Batirel 2021 | 14 | 150 | 16 | 150 | 30.3% | 0.88 [0.44, 1.73] |
| Jamil 2021 | 40 | 209 | 13 | 176 | 31.5% | 2.59 [1.43, 4.69] |
| Pinzon 2021 | 10 | 105 | 11 | 111 | 29.7% | 0.56 [0.27, 1.14] |
| Toda 2021 | 0 | 8 | 4 | 9 | 8.5% | 0.12 [0.01, 1.99] |
| Total (95% CI) | | 472 | 446 | 100.0% | 0.91 [0.36, 2.30] |
| Total events | 64 | 52 | |
| Heterogeneity: $\tau^2 = 0.62$, $\chi^2 = 14.24$, $df = 3$ ($P = 0.003$); $I^2 = 79\%$
| Test for overall effect: $Z = 2.00$ ($P = 0.84$) |

| (B) | Study or Subgroup | PDS | NPDS | Risk Ratio | Risk Ratio |
|-----|------------------|-----|-----|------------|------------|
|     | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
| 1.1 Non-Rescue Pulse | | | | |
| Cruz 2020 | 3 | 96 | 42 | 310 | 9.3% | 1.12 [0.63, 1.98] |
| El mezzouli 2021 | 79 | 283 | 82 | 230 | 13.2% | 0.78 [0.61, 1.01] |
| Gundogdu 2021 | 117 | 200 | 107 | 200 | 13.9% | 1.09 [0.92, 1.30] |
| Jamil 2021 | 43 | 209 | 30 | 224 | 11.2% | 1.54 [1.00, 2.35] |
| Monreal 2021 | 69 | 177 | 74 | 396 | 12.9% | 2.09 [1.58, 2.75] |
| Pinzon 2021 | 10 | 105 | 19 | 111 | 7.8% | 0.56 [0.27, 1.14] |
| Yaqoob 2021 | 26 | 49 | 27 | 87 | 11.4% | 1.71 [1.14, 2.57] |
| Subtotal (95% CI) | 1109 | 1558 | 79.6% | 1.21 [0.88, 1.65] |
| Total events | 357 | 381 | |
| Heterogeneity: $\tau^2 = 0.13$, $\chi^2 = 36.87$, $df = 6$ ($P = 0.00001$); $I^2 = 83\%$
| Test for overall effect: $Z = 1.19$ ($P = 0.24$) |

| 1.2 Rescue Pulse |
|------------------|-----|-----|-------------------|------------|------------|
| Batirel 2021 | 14 | 150 | 16 | 150 | 8.2% | 0.88 [0.44, 1.73] |
| Toda 2021 | 0 | 8 | 4 | 9 | 1.0% | 0.12 [0.01, 1.99] |
| Umbrelo 2021 | 17 | 22 | 20 | 59 | 11.2% | 2.28 [1.49, 3.48] |
| Subtotal (95% CI) | 180 | 218 | 20.4% | 1.05 [0.33, 3.37] |
| Total events | 31 | 40 | |
| Heterogeneity: $\tau^2 = 0.73$, $\chi^2 = 11.33$, $df = 2$ ($P = 0.003$); $I^2 = 82\%$
| Test for overall effect: $Z = 0.08$ ($P = 0.93$) |

| Total (95% CI) | 1289 | 1776 | 100.0% | 1.23 [0.92, 1.65] |
| Total events | 388 | 421 | |
| Heterogeneity: $\tau^2 = 0.15$, $\chi^2 = 48.17$, $df = 9$ ($P = 0.00001$); $I^2 = 81\%$
| Test for overall effect: $Z = 1.40$ ($P = 0.16$) |
| Test for subgroup differences: $\chi^2 = 0.05$, $df = 1$ ($P = 0.82$); $I^2 = 0\%$ |
However, serious side effects such as sudden death, cardiac arrhythmias, and seizures could occur with the PDS regimen, especially when the single dose of methylprednisolone exceeds 500 mg/day. Thus, we believe that there is an urgent need for clear protocols to guide the practice of steroid therapy in COVID-19 patients, especially the optimal dosage and duration of steroid therapy. Future RCTs are needed to determine the efficacy and safety of PDS versus NPDS regimens in the management of COVID-19.

Several limitations of this study should be acknowledged. First, because the literature lacks RCTs, our meta-analysis included only observational studies. Future RCTs are warranted to confirm our findings. Second, even though the random-effects model was used in our analysis, there was significant heterogeneity noted in all the outcomes. This might be driven by differences in patient characteristics, inconsistent follow-up duration, the difference in the location of the patients (hospital ward vs. ICU), use of other drugs for COVID-19 treatment, and lack of standardized dosages and type of the steroids used in the included studies. Third, we could not evaluate the side effects of PDS versus NPDS other than superimposed bacterial infection, such as hyperglycemia or myopathy due to limited reported data. Lastly, the lack of patient-level data did not allow to control for possible variations in baseline characteristics or optimal dosage of steroids and duration of treatment because other medications used for COVID-19 might have been different and not standardized between patients, which might introduce potential bias.

Despite the limitations, our study has significant strengths. First, we included a total of 10 studies with over 3000 patients with COVID-19. To our knowledge, this is the first meta-analysis comparing the effect of PDS versus NPDS on clinical outcomes in COVID-19 patients. Although heterogeneity was noted, we performed sensitivity analyses for the primary and secondary outcomes and subgroup analysis for mortality to evaluate the robustness of our results. Consistent results were observed on sensitivity analysis for all the outcomes and subgroup analysis of studies that included only DEXA in NPDS group and based on the strategy of PDS therapy (initial vs. rescue therapy) for mortality. Lastly, all the studies in our meta-analysis were of high quality based on the NOS quality assessment.

In conclusion, our meta-analysis demonstrates no significant differences in mortality, need for mechanical ventilation, LOS, and adverse events between PDS and NPDS regimens in the management of COVID-19. However, given the observational nature of the studies, RCTs are warranted to validate our findings.

**AUTHOR CONTRIBUTIONS**

Waleed Khokher and Azizullah Beran conceived and designed the study and critically revised the manuscript. Waleed Khokher and Azizullah Beran designed the study, collected, analyzed, interpreted the data, and drafted the manuscript. Safia Ifikhar, Omar Soura, Mohammed Mhanna, Saif-Eddin Malhas, Sapan Bhuta, Nithin Kesireddy, Dipen Patel, Elizabeth Borchers, and Cameron Burmeister collected the data and reviewed the literature. Fadi Safi and Ragheb Assaly supervised and critically revised the manuscript. All authors had access to the data and a role in writing the manuscript. All authors read and approved the final manuscript.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**DATA AVAILABILITY STATEMENT**

All data were available to all authors of the manuscript.

**ETHICS STATEMENT**

This study was deemed exempt by the Institutional Review Board of the University of Toledo, as it was a meta-analysis of published studies that included deidentified patient information.

**ORCID**

Azizullah Beran https://orcid.org/0000-0002-4161-942X

**REFERENCES**

1. Kiang MV, Irizarry RA, Buckee CO, Balsari S. Every body counts: measuring mortality from the COVID-19 pandemic. *Ann Intern Med*. 2020;173(12):1004-1007.
2. Kumar A, Singh R, Kaur J, et al. Wuhan to world: the COVID-19 pandemic. *Front Cell Infect Microbiol*. 2021;11:596201.
3. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. *Expert Rev Respir Med*. 2020;14(11):1149-1163.
4. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. *Crit Care*. 2020;24(1):516.
5. Costela-Vízquez JI, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev*. 2020;54:62-75.
6. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2020;384(8):693-704.
7. Li H, Yan B, Gao R, Ren J, Yang J. Effectiveness of corticosteroids to treat severe COVID-19: a systematic review and meta-analysis of prospective studies. *Int Immunopharmacol*. 2021;100:108121.
8. Tlayjeh H, Mish H, Enani MA, et al. Association of corticosteroids use and outcomes in COVID-19 patients: a systematic review and meta-analysis. *J Infect Public Health*. 2020;13(11):1652-1663.
9. Sinha A, Bagg A. Pulse steroid therapy. *Indian J Pediatr*. 2008;75(10):1057-1066.
10. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. *Am J Respir Crit Care Med*. 2003;168(12):1449-1456.
11. Arabi YM, Maudourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. *Am J Respir Crit Care Med*. 2018;197(6):757-767.
12. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. *Clin Immunol*. 2020;214:108393.
13. Oba Y. The use of corticosteroids in SARS. *N Engl J Med*. 2003;348(20):2034-2035.
14. El Mezzeoui S, El Aidouni G, Merbouh M, et al. Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: a retrospective and comparative study of 513 cases. *Ann Med Surg (Lond)*. 2021;70:102858.
15. Pinzón MA, Ortiz S, Holguín H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16(5):e0252057.
16. Domae K, Miyagawa S, Yoshikawa Y, et al. Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients. Clin Exp Nephrol. 2021;10:1-11.
17. Batirel A, Demirhan R, Eser N, Körlü E, Tezcan ME. Pulse steroid treatment for hospitalized adults with COVID-19. Turk J Med Sci. 2021;51(5):2248-2255.
18. Fernández-Cruz A, Ruiz-Antonán B, Muñoz-Gómez A, et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother. 2020;64(9):e01168-20.
19. Gundogdu O, Demir B, Coskun CO, Ersan I. Efficacy of pulse steroid therapy in patients critically ill with COVID-19. Bratisl Lek Listy. 2021;122(11):793-798.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.
22. Monreal E, Sainz de la Maza S, Natera-Villalba E, et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2021;40(4):761-769.
23. Umbrello M, Formenti P, Nespoli S, Pisano E, Bonino C, Mutinii S. Effect of different corticosteroid regimens on the outcome of severe COVID-19-related acute respiratory failure. A retrospective analysis. J Clin Med. 2021;10:21.
24. Yaqoob H, Greenberg D, Hwang F, et al. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit. J Med Virol. 2022;94(1):349-356.
25. Jamil Z, Almajhdi FN, Khalid S, Asghar M, Ahmed J, Waheed Y. Comparison of low-versus high-dose steroids in the clinical outcome of hospitalized COVID-19 patients. Antibiotics (Basel). 2021;10:12.
26. Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56:6.
27. Baethge BA, Lidsky MD, Goldberg JW. A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Ann Pharmacother. 1992;26(3):316-320.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Khokher W, Beran A, Iftikhar S, et al. Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol. 2022;94:4125-4137. doi:10.1002/jmv.27824